SCHEMBL5453726

SCHEMBL5453726

O=C(NO)c1ccc(-c2ccc(CNCCN3CCCC3)cc2)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.50
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 5/20 0.47
MAPT P10636 3/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KDM4E B2RXH2 4/20 0.42
HPGD P15428 3/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446779 0.99 DPP7 (0.49) DPP7KMT2AALDH1A1MAPTTSHR
SCHEMBL5453734 0.93 ALDH1A1 (0.53) DPP7KMT2AALDH1A1MAPTTSHR
SCHEMBL5444760 0.91 ALDH1A1 (0.59) KMT2AALDH1A1MAPTTSHRMAPK1
SCHEMBL8288789 0.88 DPP7 (0.48) DPP7KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL8288792 0.87 ATR (0.47) DPP7KMT2AALDH1A1TSHRSMN1; SMN2
SCHEMBL5452564 0.84 ALDH1A1 (0.66) KMT2AALDH1A1MAPTTSHRMAPK1
SCHEMBL5445375 0.80 MAPT (0.59) KMT2AALDH1A1MAPTTSHRMAPK1
SCHEMBL8288829 0.78 HDAC1 (0.52) DPP7KMT2AHDAC1HDAC8HDAC6
SCHEMBL5456286 0.78 KDM4E (0.45) KMT2AALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL8289928 0.77 HDAC1 (0.51) DPP7KMT2AHDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications HDAC1, HDAC11, HDAC2 DPP7 1463/4885KMT2A 80/4885ALDH1A1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.